The Science Behind NMP-SR: Enhanced Bioavailability, Dosing and Tolerability
Oral NMP-SR appears to be a valuable option for treating obstetric conditions associated with insufficient progesterone exposure.
PUBLICATIONSDIVAGESTREPRODUCTIVE AGE GROUP
A real-world national survey of 925 Indian gynaecologists found that:
· 23% prefer oral NMP-SR for managing luteal phase defects
· 11% prefer it for luteal phase support during ART
· 10% prefer it for prevention of preterm delivery
· 56% prefer it for all three indications
In women with a poor obstetric history associated with luteal phase deficiency:
· 58% prefer to use vaginal progesterone
· 36% prefer oral NMP-SR
· 6% prefer Dydrogesterone
Thus, oral NMP-SR has an important role in managing obstetric conditions in India.
By releasing progesterone gradually and circumventing first-pass metabolism, NMP-SR elicits the desired therapeutic effect with benefits over conventional oral NMP in terms of bioavailability, once-daily dosing and improved tolerability.
This review examines available evidence, till September 2019, from clinical studies investigating oral NMP and oral NMP-SR in obstetric indications of assisted reproduction, recurrent or threatened miscarriage, preterm birth, and high-risk pregnancy.
Oral NMP was effective for luteal phase support during in vitro fertilization and intrauterine insemination, prevention of threatened miscarriage, and prevention of preterm delivery. NMP-SR was comparable to dydrogesterone for luteal phase support during intrauterine insemination and effectively maintained high-risk pregnancies. Oral NMP-SR was well tolerated.